Corporate Fact Sheet Q1-2021

OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
- Robust patent portfolio *(12 patents and patent applications)*
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
- Significantly undervalued compared to its peers

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases (COVID-19)	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Methamphetamine Use Disorder	Phase 1	CTA with University of Wisconsin
Psilocybin *(Oral Formulations)*	Depression, Anxiety, etc.	Pre-clinical	Target FDA Approval
CBD	Liver Diseases (Autoimmune Hepatitis)	Filing IND	Plan for Phase 2

STRATEGIC PARTNERS

Pharm-Olam: Infectious Diseases CRO	Psilocin Corp.: Acquired March 2020 Psychedelic pharma	Wisconsin: R&D partnership Psychedelic pharma
University of South Carolina: License of cannabidiol for treatment of Autoimmune Hepatitis	WARF: License of cannabinoid delivery technology	PharmaTher: Psilocybin Collaboration

UPCOMING MILESTONES

Q1-21 FDA Phase 3 COVID-19 interim results

Q1-21 Initiate FDA Phase 2 study for CBD in AIH

Q1-21 Submit FDA IND Psilocybin (oral formulation)

Q1-21 Start Phase 1 study – Psilocybin in Meth Disorder

Q1-21 FDA Phase 3 COVID-19 interim results

Q1-21 FDA Pre-IND – Bucillamine for infectious diseases

Q2-21 Complete FDA Phase 3 study COVID-19

TEAM

Management

Michael Frank (Chairman & CEO)
Carmelo Marrelli (CFO)
Derrick Welch (Founder, Psilocin Pharma)

Scientific and Clinical

Dr. Kelly McKee (CSO)
Dr. Osnesmo Mpanju (Regulatory)
Dr. David Boulware, MD (Scientific Advisor)

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna, Andrew Lindzon

VALUATION COMPARISON



STOCK INFORMATION

Ticker:	CSE: RVV, OTC: RVVTF
Share Price:	$0.60 *(Jan 8, 2021)*
52-week High / Low:	CAD $0.92 / $0.035
Shares Outstanding:	259,219,666
Market Cap:	CAD ~ $155,000,000

Revive Therapeutics Ltd. | 82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036 | mfrank@revivethera.com | revivethera.com